Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

GermanyBack to Germany

Clinical trials in Hamburg – page 44

1 128 clinical trials in Hamburg, Germany across 19 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Hamburg at a glance
1 128
clinical trials
  • Research sites19
Type of trial
Recruitment status
Quick filters

1 128 trials in Hamburg

Open in trial search

Interstitial lung disease+2

Not yet recruiting

Long‑term Safety and Tolerability of Admilparant in Adults with Idiopathic or Progressive Pulmonary Fibrosis

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:ADMILPARANT
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Systemic candida

Not yet recruiting

Shortening treatment duration in adults with uncomplicated candidemia: caspofungin acetate versus saline and sodium lactate placebo

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Caspofungin Acetate
  • Sponsor:University Of Cologne

Hormone-dependent prostate cancer+3

Not yet recruiting

BMS-986365 in Metastatic Castration-Sensitive Prostate Cancer in Patients with Suboptimal PSA Response After ADT and ARPI

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:BMS-986365
  • Sponsor:AIO-Studien gGmbH

Neoplasm+2

Not yet recruiting

REGN10597 Alone or with Cemiplimab in Adults with Advanced Solid Tumours, Melanoma, or Clear-Cell Renal-Cell Carcinoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cemiplimab
  • Sponsor:Regeneron Pharmaceuticals Inc.

Septic shock+1

Not yet recruiting

Angiotensin II in Children and Adolescents With Refractory Hypotension in Distributive Shock

Registered drug
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:ANGIOTENSIN II

B precursor type acute leukaemia

Not yet recruiting

Study of asciminib, dexamethasone, blinatumomab, and vincristine sulfate in children and young adults with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Blinatumomab
  • Sponsor:Novartis Pharma AG

Idiopathic pulmonary fibrosis

Not yet recruiting

A study to evaluate the safety and effectiveness of zampilimab in people with idiopathic pulmonary fibrosis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:ZAMPILIMAB
  • Sponsor:Chiesi Farmaceutici S.p.A.

Wound infection pseudomonas

Not yet recruiting

Safety and efficacy of elfucose, d‑galactose and polyhexanide solution 20% in patients with chronic wounds colonized by Pseudomonas aeruginosa

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Sponsor:PathoBlock Therapeutics GmbH & Co. KG

Pulmonary fibrosis

Not yet recruiting

A study to evaluate the effectiveness and safety of admilparant in patients with progressive pulmonary fibrosis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:ADMILPARANT
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Idiopathic pulmonary fibrosis

Not yet recruiting

A study to evaluate the effectiveness and safety of admilparant in patients with idiopathic pulmonary fibrosis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:ADMILPARANT
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Plasma cell myeloma refractory

Not yet recruiting

A Study of Linvoseltamab Alone and Linvoseltamab with Carfilzomib Compared to Standard Treatment in Adults with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Aciclovir
  • Sponsor:Regeneron Pharmaceuticals Inc.

Uveal melanoma

Not yet recruiting

A study comparing RP2 with nivolumab versus ipilimumab with nivolumab in adults with metastatic uveal melanoma not previously treated with immune checkpoint inhibitors

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ipilimumab
  • Sponsor:Replimune Group Inc.

Other cities in Germany

The busiest research cities in the country

All 516 cities in Germany

Clinical research in Hamburg

What the registry says about research in the country

01 Oncology Research

Current clinical trials focusing on innovative treatments for metastatic prostate cancer, colorectal cancer, and breast cancer. Studies are evaluating new therapeutic combinations and targeted approaches for improved patient outcomes.

  • Advanced cancer therapies
  • Immunotherapy combinations
  • Treatment resistance strategies
02 Infectious Disease Prevention

Comprehensive vaccine development programs targeting respiratory syncytial virus, cytomegalovirus, and meningococcal infections. Research focuses on both adult and pediatric populations.

  • Vaccine immunogenicity
  • Long-term protection
  • Novel vaccine platforms
03 Neurological Conditions

Groundbreaking research in treating acute cerebral ischemic stroke with innovative therapies. Studies are evaluating functional outcomes and safety profiles of new therapeutic agents.

  • Stroke treatment
  • Neuroprotective strategies
  • Recovery outcomes
04 Women's Health

Clinical investigations addressing vaginal atrophy and contraceptive technologies. Research includes novel delivery systems and hormone-based treatments for postmenopausal conditions.

  • Reproductive health
  • Hormone therapy
  • Novel delivery systems
Back to GermanyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.